{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T06:20:36Z","timestamp":1791267636850,"version":"4.1.0"},"reference-count":32,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2008,10,13]],"date-time":"2008-10-13T00:00:00Z","timestamp":1223856000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2008,11,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND.<\/jats:title><jats:p>In this international, multicenter trial, the authors evaluated rituximab (anti\u2010CD20) plus epratuzumab (anti\u2010CD22) in patients with postchemotherapy relapsed\/refractory, indolent non\u2010Hodgkin lymphoma (NHL), including long\u2010term efficacy.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS.<\/jats:title><jats:p>Forty\u2010nine patients with follicular NHL (FL) (N = 41) or small lymphocytic lymphoma (SLL) (N = 7) received intravenous epratuzumab 360 mg\/m<jats:sup>2<\/jats:sup> and then intravenous rituximab 375 mg\/m<jats:sup>2<\/jats:sup> weekly \u00d74. The regimen was tolerated well.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS.<\/jats:title><jats:p>Twenty\u2010two of 41 patients with FL (54%) had an objective response (OR), including 10 (24%) complete responses (CR) (CR\/unconfirmed CR [CRu]), whereas 4 of 7 patients with SLL (57%) had ORs, including 3 (43%) with CR\/CRu. Rituximab\u2010naive patients (N = 34) had an OR rate of 50% (26% CR\/CRu rate), whereas patients who previously responded to rituximab (N = 14) had an OR rate of 64% (29% CR\/CRu rate). An OR rate of 85% was observed in patients with FL who had Follicular Lymphoma International Prognostic Index (FLIPI) risk scores of 0 or 1 (N = 13), whereas 28 patients with intermediate or high\u2010risk FLIPI scores (\u22652) had an OR rate of 39% (18% CR\/CRu rate). In patients with FL, the median response duration was 13.4 months, and that duration increased to 29.1 months for 10 patients who had a CR\/CRu, including 4 patients who had durable responses with remissions that continued for &gt;4 years. In patients with SLL, the median response duration was 20 months, including 1 patient who had a response that continued for &gt;3 years.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS.<\/jats:title><jats:p>The combination of epratuzumab and rituximab induced durable responses in patients with recurrent, indolent NHL. Cancer 2008. \u00a9 2008 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.23890","type":"journal-article","created":{"date-parts":[[2008,10,13]],"date-time":"2008-10-13T19:54:13Z","timestamp":1223927653000},"page":"2714-2723","source":"Crossref","is-referenced-by-count":97,"title":["Durable complete responses from therapy with combined epratuzumab and rituximab"],"prefix":"10.1002","volume":"113","author":[{"given":"John P.","family":"Leonard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Schuster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos","family":"Emmanouilides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Couture","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Teoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William A.","family":"Wegener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morton","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Goldenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,11,3]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.11.3909"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.8.2825"},{"key":"e_1_2_6_4_2","first-page":"350a","article-title":"Differential expression of CD22 indolent and aggressive non\u2010Hodgkin's lymphoma (NHL): implications for targeted therapy","volume":"100","author":"Cessano A","year":"2002","journal-title":"Blood."},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.150.11.4715"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0065-2776(05)88001-0"},{"key":"e_1_2_6_7_2","first-page":"4568","article-title":"Two new monoclonal antibodies, EPB\u20101 and EPB\u20102, reactive with human lymphoma","volume":"49","author":"Pawlak\u2010Byczkowska EJ","year":"1989","journal-title":"Cancer Res."},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01518451"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/0161-5890(95)00080-1"},{"key":"e_1_2_6_10_2","first-page":"353a","article-title":"Epratuzumab's predominant antitumor activity in vitro\/in vivo against non\u2010Hodgkin's lymphoma (NHL) is via antibody\u2010dependent cellular cytotoxicity (ADCC)","volume":"100","author":"Gada P","year":"2002","journal-title":"Blood."},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-03-0493"},{"key":"e_1_2_6_12_2","first-page":"158a","article-title":"Enhancement in anti\u2010tumor activity of rituximab when combined with epratuzumab or apolizumab (Hu1D10) in a B\u2010cell lymphoma severe combined immunodeficiency (SCID) mouse model","volume":"100","author":"Hernandez\u2010Ilizaliturri F","year":"2002","journal-title":"Blood."},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2006.05.007"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.01.082"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-0294"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.13.821"},{"key":"e_1_2_6_17_2","first-page":"69a","article-title":"Multi\u2010center phase 2 study of combination antibody therapy with epratuzumab plus rituximab in recurring low\u2010grade NHL","volume":"102","author":"Emmanouilides C","year":"2003","journal-title":"Blood."},{"key":"e_1_2_6_18_2","doi-asserted-by":"crossref","first-page":"1002a","DOI":"10.1182\/blood.V110.11.3419.3419","article-title":"Durable complete responses following therapy with epratuzumab plus rituximab: final efficacy results of a multicenter study in recurrent indolent non\u2010Hodgkin's lymphoma (NHL)","volume":"110","author":"Leonard JP","year":"2007","journal-title":"Blood."},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-12-4434"},{"key":"e_1_2_6_21_2","first-page":"691","volume-title":"Neoplastic Hematopathology","author":"Harris NL","year":"2001"},{"key":"e_1_2_6_22_2","first-page":"644a","article-title":"Pharmacokinetics of rituximab and epratuzumab during concomitant administration of the 2 antibodies in patients with B\u2010cell NHL","volume":"102","author":"Doshi S","year":"2003","journal-title":"Blood."},{"key":"e_1_2_6_23_2","first-page":"575","article-title":"Pharmacokinetics of epratuzumab administered as a single agent or in combination with rituximab in patients with B\u2010cell NHL","volume":"22","author":"Perotti B","year":"2003","journal-title":"Proc Am Soc Clin Oncol."},{"key":"e_1_2_6_24_2","unstructured":"Genentech. Rituxan (rituximab) full prescribing information. Available at:http:\/\/www.gene.com\/gene\/products\/information\/oncology\/rituxan\/insert.jsp. Accessed on October 1 2008."},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.04.020"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.06.004"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1053\/sonc.2002.34878"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdm114"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V90.6.2188"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.05.6291"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.17.3135"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02981940"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22342"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.23890","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.23890","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T13:31:45Z","timestamp":1760275905000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.23890"}},"subtitle":["Final results from an international multicenter, phase 2 study in recurrent, indolent, non\u2010Hodgkin lymphoma"],"short-title":[],"issued":{"date-parts":[[2008,11,3]]},"references-count":32,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2008,11,15]]}},"alternative-id":["10.1002\/cncr.23890"],"URL":"https:\/\/doi.org\/10.1002\/cncr.23890","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,11,3]]}}}